CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates (original) (raw)

Nature Medicine volume 17, pages 1128–1131 (2011)Cite this article

Subjects

Abstract

Vaccine-induced immunity to Ebola virus infection in nonhuman primates (NHPs) is marked by potent antigen-specific cellular and humoral immune responses1,2; however, the immune mechanism of protection remains unknown. Here we define the immune basis of protection conferred by a highly protective recombinant adenovirus virus serotype 5 (rAd5) encoding Ebola virus glycoprotein (GP)1,3 in NHPs. Passive transfer of high-titer polyclonal antibodies from vaccinated Ebola virus–immune cynomolgus macaques to naive macaques failed to confer protection against disease, suggesting a limited role of humoral immunity. In contrast, depletion of CD3+ T cells in vivo after vaccination and immediately before challenge eliminated immunity in two vaccinated macaques, indicating a crucial requirement for T cells in this setting. The protective effect was mediated largely by CD8+ cells, as depletion of CD8+ cells in vivo using the cM-T807 monoclonal antibody (mAb), which does not affect CD4+ T cell or humoral immune responses, abrogated protection in four out of five subjects. These findings indicate that CD8+ cells have a major role in rAd5-GP–induced immune protection against Ebola virus infection in NHPs. Understanding the immunologic mechanism of Ebola virus protection will facilitate the development of vaccines for Ebola and related hemorrhagic fever viruses in humans.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Sullivan, N.J. et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424, 681–684 (2003).
    Article CAS PubMed PubMed Central Google Scholar
  2. Sullivan, N.J., Sanchez, A., Rollin, P.E., Yang, Z.Y. & Nabel, G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605–609 (2000).
    Article CAS PubMed Google Scholar
  3. Sullivan, N.J. et al. Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med. 3, e177 (2006).
    Article PubMed PubMed Central Google Scholar
  4. Jones, S.M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786–790 (2005).
    Article CAS PubMed Google Scholar
  5. Geisbert, T.W. et al. Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates. J. Virol. 84, 10386–10394 (2010).
    Article CAS PubMed PubMed Central Google Scholar
  6. Sullivan, N.J., Martin, J.E., Graham, B.S. & Nabel, G.J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat. Rev. Microbiol. 7, 393–400 (2009).
    Article CAS PubMed PubMed Central Google Scholar
  7. Oswald, W.B. et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog. 3, e9 (2007).
    Article PubMed PubMed Central Google Scholar
  8. Neville, D.M. Jr. et al. A new reagent for the induction of T cell depletion, anti-CD3–CRM9. J. Immunother. Emphasis Tumor Immunol. 19, 85–92 (1996).
    Article CAS PubMed Google Scholar
  9. Hensley, L.E. et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus species. PLoS Pathog. 6, e1000904 (2010).
    Article PubMed PubMed Central Google Scholar
  10. Schmitz, J.E. et al. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154, 1923–1932 (1999).
    Article CAS PubMed PubMed Central Google Scholar
  11. Gupta, M. et al. Persistent infection with Ebola virus under conditions of partial immunity. J. Virol. 78, 958–967 (2004).
    Article CAS PubMed PubMed Central Google Scholar
  12. Wilson, J.A. & Hart, M.K. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J. Virol. 75, 2660–2664 (2001).
    Article CAS PubMed PubMed Central Google Scholar
  13. Warfield, K.L. et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J. Immunol. 175, 1184–1191 (2005).
    Article CAS PubMed Google Scholar
  14. Jahrling, P.B. et al. Passive immunization of Ebola virus–infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Virol. Suppl. 11, 135–140 (1996).
    CAS PubMed Google Scholar
  15. Geisbert, T.W. et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8, 503–507 (2002).
    Article PubMed PubMed Central Google Scholar
  16. Geisbert, T.W. et al. Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. Am. J. Pathol. 163, 2347–2370 (2003).
    Article CAS PubMed PubMed Central Google Scholar
  17. Sanchez, A., Kiley, M.P., Holloway, B.P. & Auperin, D.D. Sequence analysis of the Ebola virus genome: organization, genetic elements and comparison with the genome of Marburg virus. Virus Res. 29, 215–240 (1993).
    Article CAS PubMed Google Scholar
  18. Xu, L. et al. Immunization for Ebola virus infection. Nat. Med. 4, 37–42 (1998).
    Article CAS PubMed Google Scholar
  19. Ohno, T. et al. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265, 781–784 (1994).
    Article CAS PubMed Google Scholar
  20. Chattopadhyay, P.K, Yu, J. & Roederer, M. Application of quantum dots to multicolor flow cytometry. in Methods in Molecular Biology (eds. Bruchez, M. & Hotz, C.) 374, 175–184 (Humana Press, Totowa, New Jersey, 2007).
    PubMed Google Scholar
  21. Geisbert, T.W. et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 375, 1896–1905 (2010).
    Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We thank D. Jeffers, T. Suhana, A. Tislerics and B. Hartman for help with manuscript preparation; M. Cichanowski for graphics; D. Braun, K. Daddario and C. Rice for technical and animal care assistance; S. Norris and M. Nason for assistance with statistical considerations; and K. Kenyon for editorial support. We thank D. Neville (US National Institute of Mental Health) for the generous gift of FN18-CRM9 immunotoxin. Reagent support was provided by the Nonhuman Primate Reagent Resource (grant number R24RR016001 from the National Center for Research Resource, US National Institutes of Health). Support for this work was provided by the Intramural Research Program of the US National Institutes of Health. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army or the Department of Defense.

Author information

Author notes

  1. Thomas W Geisbert, Michael Bailey & Joan B Geisbert
    Present address: Present addresses: University of Texas Medical Branch, Galveston, Texas, USA (T.W.G. and J.B.G.) and Transformational Medical Technologies, Joint Program Executive Office, US Department of the Army, Fort Belvoir, Virginia, USA (M.B.).,

Authors and Affiliations

  1. Vaccine Research Center, US National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Nancy J Sullivan, Clement Asiedu, Daphne Stanley, Michael Bailey, Saran Bao, Srinivas Rao, Mario Roederer, Richard A Koup & Gary J Nabel
  2. United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA
    Lisa Hensley, Thomas W Geisbert, Joshua Johnson, Anna Honko, Gene Olinger & Joan B Geisbert
  3. Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Keith A Reimann
  4. Integrated Research Facility, US National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland, USA
    Peter B Jahrling

Authors

  1. Nancy J Sullivan
    You can also search for this author inPubMed Google Scholar
  2. Lisa Hensley
    You can also search for this author inPubMed Google Scholar
  3. Clement Asiedu
    You can also search for this author inPubMed Google Scholar
  4. Thomas W Geisbert
    You can also search for this author inPubMed Google Scholar
  5. Daphne Stanley
    You can also search for this author inPubMed Google Scholar
  6. Joshua Johnson
    You can also search for this author inPubMed Google Scholar
  7. Anna Honko
    You can also search for this author inPubMed Google Scholar
  8. Gene Olinger
    You can also search for this author inPubMed Google Scholar
  9. Michael Bailey
    You can also search for this author inPubMed Google Scholar
  10. Joan B Geisbert
    You can also search for this author inPubMed Google Scholar
  11. Keith A Reimann
    You can also search for this author inPubMed Google Scholar
  12. Saran Bao
    You can also search for this author inPubMed Google Scholar
  13. Srinivas Rao
    You can also search for this author inPubMed Google Scholar
  14. Mario Roederer
    You can also search for this author inPubMed Google Scholar
  15. Peter B Jahrling
    You can also search for this author inPubMed Google Scholar
  16. Richard A Koup
    You can also search for this author inPubMed Google Scholar
  17. Gary J Nabel
    You can also search for this author inPubMed Google Scholar

Contributions

N.J.S. and G.J.N. conceived of the studies and wrote the manuscript. T.W.G., J.B.G., L.H., J.J., G.O. and A.H. contributed to animal study design, conducted infectious Ebola virus challenge, post-challenge assays and passive antibody administration. N.J.S., M.B., C.A. and D.S. performed vaccine preparation, animal immunization, characterization of vaccine-induced immune responses and immunodepleting antibody administration. K.A.R. provided depleting antibodies and contributed to experimental design. S.B. and S.R. performed immunohistochemistry. M.R., P.B.J. and R.A.K. contributed to experimental design or provided reagents.

Corresponding author

Correspondence toNancy J Sullivan.

Ethics declarations

Competing interests

N.J.S., G.J.N., T.W.G. and P.B.J. have intellectual property on gene-based vaccines for Ebola.

Supplementary information

Rights and permissions

About this article

Cite this article

Sullivan, N., Hensley, L., Asiedu, C. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates.Nat Med 17, 1128–1131 (2011). https://doi.org/10.1038/nm.2447

Download citation